类风湿关节炎患者血清依那西普浓度与超声、生物标志物及临床疾病活动度评分评估的疾病活动度和治疗反应的关系:一项前瞻性观察研究结果
这项前瞻性观察研究纳入89例起始依那西普治疗的类风湿关节炎患者,其中66%为生物制剂初治、91%联用合成改善病情抗风湿药。3个月时依那西普浓度中位数为1.8(IQR 1.1-2.5)mg/L;依那西普浓度与血浆钙卫蛋白、C反应蛋白和DAS28评估的疾病活动度存在纵向关联,但与3、6或12个月时任何参数的疾病活动度改善无关,达到缓解或应答者的浓度与未达到者无显著差异,未发现治疗窗,无患者产生抗依那西普抗体。
要点
- 3个月时依那西普浓度中位数1.8(IQR 1.1-2.5)mg/L,未发现治疗窗。
- 浓度与血浆钙卫蛋白、C反应蛋白和DAS28评估的疾病活动度存在纵向关联。
- 浓度与3、6或12个月时任何参数的疾病活动度改善无关,无患者产生抗依那西普抗体。
核心结论
- 尽管使用了敏感且客观的炎症标志物,仍未能为依那西普确定治疗窗。
- 因此,本研究表明主动治疗药物监测不太可能使接受依那西普治疗的类风湿关节炎患者获益,但不能排除在某些临床情况下的潜在获益。
研究设计与样本
- 前瞻性观察性纵向研究,纳入89例起始依那西普治疗的类风湿关节炎患者,其中66%为生物制剂初治、91%联用合成改善病情抗风湿药。
- 疾病活动度通过超声(灰阶和能量多普勒)、28关节疾病活动度评分(DAS28)、简化疾病活动度指数、血浆钙卫蛋白和C反应蛋白评估。
- 依那西普浓度和抗依那西普抗体采用自动化院内荧光测定法分析。
主要发现
- 3个月时依那西普浓度中位数为1.8(IQR 1.1-2.5)mg/L。
- 依那西普浓度与血浆钙卫蛋白、C反应蛋白和DAS28评估的疾病活动度之间存在纵向关联。
- 依那西普浓度与3、6或12个月治疗时任何参数的疾病活动度改善之间无关联。
- 达到应答或缓解的患者与未达到应答或缓解的患者相比,依那西普浓度无显著差异。
- 没有患者产生抗依那西普抗体。
关键数值与推荐
- 未确定依那西普的治疗窗。
- 3个月时依那西普浓度中位数为1.8(IQR 1.1-2.5)mg/L。
- 无患者产生抗依那西普抗体。
临床怎么用
- 本研究表明主动治疗药物监测不太可能使接受依那西普治疗的类风湿关节炎患者获益,但不能排除在某些临床情况下的潜在获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify the therapeutic range for etanercept and to assess the incidence of anti-etanercept antibody formation. METHODS: Associations between etanercept serum concentration and disease activity as well as treatment response were examined in a longitudinal observational study of rheumatoid arthritis patients starting etanercept. Disease activity was assessed by ultrasound (grey scale and power Doppler), 28-joint Disease Activity Score (DAS28), Simplified Disease Activity Index, plasma calprotectin and C reactive protein. Etanercept concentration and anti-etanercept antibodies were analysed using automated in-house fluorescence assays. RESULTS: A total of 89 patients were included, whereof 66% were biological disease-modifying antirheumatic drug (DMARD) naïve and 91% used concomitant synthetic DMARD. At 3 months, the median etanercept concentration was 1.8 (IQR 1.1-2.5) mg/L. Longitudinal associations were found between etanercept concentration and disease activity assessed by plasma calprotectin, C reactive protein and DAS28, but not between etanercept concentration and improvement in disease activity by any of the parameters at 3, 6 or 12 months of treatment. Etanercept concentrations were not significantly different among patients who achieved response or remission, compared with non-response or non-remission. Hence, no therapeutic range could be identified. None of the patients developed anti-etanercept antibodies. CONCLUSION: Despite the use of sensitive and objective markers of inflammation, a therapeutic range could not be identified for etanercept. Hence, this study suggests that proactive therapeutic drug monitoring is unlikely to benefit rheumatoid arthritis patients treated with etanercept, but a potential benefit in certain clinical situations cannot be excluded.
引用
- Gehin JE, Syversen SW, Warren DJ, et al. Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis. RMD Open. 2021. PMID: 34911811. doi:10.1136/rmdopen-2021-001985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。